As cases of anxiety and depression continue to rise and remain the most prevalent mental health conditions on Guam, a permanent psychiatrist has been hired to oversee Guam’s first-ever transcranial ...
If approved, lying in wait for Vraylar in the treatment-resistant depression category will be Johnson & Johnson's Spravato (esketamine), which was approved by the FDA in 2019, albeit with a label ...